Influencing Factors of Ovarian Tissue Vitrification and Transplantation Techniques

doi:10.12280/gjszjk.20240451

Abstract

Abstract:

Ovarian tissue vitrification and transplantation techniques are crucial for fertility preservation, especially for young women with the cancer requiring gonadotoxic treatments and for prepubertal children. This technique involves multiple factors that affect the outcomes of cryopreservation and transplantation. In terms of cryoprotectant selection, the composition, concentration and equilibration time have significant effects on the freezing outcome. The processing of ovarian tissue and the choice of freezing carrier are also crucial factors influencing the success of cryopreservation and transplantation. During thawing and recovery, the removal rate of cryoprotectants must be carefully controlled to prevent cellular damage. The choice of transplantation site can be determined, based on the patient′s actual needs. Ischemia, hypoxia and oxidative stress during the initial period after transplantation are important factors leading to follicular loss, which can be improved by the use of angiogenic factors, stem cells, antioxidants, and other interventions. Additionally, clinical factors such as the age, number of transplantations and mode of conception can also impact the pregnancy rates following transplantation. These factors provide a scientific basis and practical guidance for optimizing the success rate of ovarian tissue cryopreservation and transplantation, offering new insights and directions for future research and clinical practice.

Key words: Cryopreservation, Tissue preservation, Tissue transplantation, Ovary, Oxidative stress, Vitrification, Fertility preservation

WANG Lin, XU Jian. Influencing Factors of Ovarian Tissue Vitrification and Transplantation Techniques[J]. Journal of International Reproductive Health/Family Planning, 2025, 44(1): 47-53.

References 53

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
[2]	Amorim CA, Leonel E, Afifi Y, et al. Cryostorage and retransplantation of ovarian tissue as an infertility treatment[J]. Best Pract Res Clin Endocrinol Metab, 2019, 33(1):89-102. doi: 10.1016/j.beem.2018.09.002. pmid: 31208678
[3]	El Cury-Silva T, Nunes M, Casalechi M, et al. Cryoprotectant agents for ovarian tissue vitrification: Systematic review[J]. Cryobiology, 2021, 103:7-14. doi: 10.1016/j.cryobiol.2021.08.001. pmid: 34370991
[4]	Yong KW, Laouar L, Elliott J, et al. Review of non-permeating cryoprotectants as supplements for vitrification of mammalian tissues[J]. Cryobiology, 2020, 96:1-11. doi: 10.1016/j.cryobiol.2020.08.012. pmid: 32910946
[5]	Zeng Q, Wang K, He LB, et al. Cryoprotective effect of antifreeze protein Ⅲ on the rabbit ovary[J]. Reprod Fertil Dev, 2022, 34(9):645-657. doi: 10.1071/RD21324.
[6]	Kong HS, Hong YH, Lee J, et al. Antifreeze Protein Supplementation During the Warming of Vitrified Bovine Ovarian Tissue Can Improve the Ovarian Tissue Quality After Xenotransplantation[J]. Front Endocrinol(Lausanne), 2021,12:672619. doi: 10.3389/fendo.2021.672619.
[7]	Montano Vizcarra DA, Pinto Silva Y, Bezerra Bruno J, et al. Use of synthetic polymers improves the quality of vitrified caprine preantral follicles in the ovarian tissue[J]. Acta Histochem, 2020, 122(2):151484. doi: 10.1016/j.acthis.2019.151484.
[8]	Shahsavari MH, Alves KA, Alves BG, et al. Impacts of different synthetic polymers on vitrification of ovarian tissue[J]. Cryobiology, 2020, 94:66-72. doi: 10.1016/j.cryobiol.2020.04.007. pmid: 32339491
[9]	Fahy GM, Wowk B. Principles of Ice-Free Cryopreservation by Vitrification[J]. Methods Mol Biol, 2021,2180:27-97. doi: 10.1007/ 978-1-0716-0783-1_2.
[10]	Lee S, Ryu KJ, Kim B, et al. Comparison between Slow Freezing and Vitrification for Human Ovarian Tissue Cryopreservation and Xenotransplantation[J]. Int J Mol Sci, 2019, 20(13):3346. doi: 10.3390/ijms20133346.
[11]	Zhao Q, Zhang Y, Su K, et al. Vitrification freezing of large ovarian tissue in the human body[J]. J Ovarian Res, 2019, 12(1):77. doi: 10.1186/s13048-019-0553-x. pmid: 31438999
[12]	Fabbri R, Vicenti R, Macciocca M, et al. Morphological, ultrastructural and functional imaging of frozen/thawed and vitrified/warmed human ovarian tissue retrieved from oncological patients[J]. Hum Reprod, 2016, 31(8):1838-1849. doi: 10.1093/humrep/dew134.
[13]	Behl S, Joshi VB, Larson NB, et al. Vitrification versus slow freezing of human ovarian tissue: a systematic review and meta-analysis of histological outcomes[J]. J Assist Reprod Genet, 2023, 40(3):455-464. doi: 10.1007/s10815-022-02692-w.
[14]	Diaz AA, Kubo H, Handa N, et al. A Systematic Review of Ovarian Tissue Transplantation Outcomes by Ovarian Tissue Processing Size for Cryopreservation[J]. Front Endocrinol(Lausanne), 2022, 13:918899. doi: 10.3389/fendo.2022.918899.
[15]	Hsueh A, Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients[J]. Fertil Steril, 2020, 114(3):458-464. doi: 10.1016/j.fertnstert.2020.07.031. pmid: 32782158
[16]	Nagamatsu G, Shimamoto S, Hamazaki N, et al. Mechanical stress accompanied with nuclear rotation is involved in the dormant state of mouse oocytes[J]. Sci Adv, 2019, 5(6):eaav9960. doi: 10.1126/sciadv.aav9960.
[17]	Lopes ÉPF, Tetaping GM, Novaes M, et al. Systematic review and meta-analysis on patented and non-patented vitrification processes to ovarian tissue reported between 2000 and 2021[J]. Anim Reprod, 2023, 20(3):e20230065. doi: 10.1590/1984-3143-AR2023-0065.
[18]	Porcu E, Tranquillo ML, Notarangelo L, et al. High-security closed devices are efficient and safe to protect human oocytes from potential risk of viral contamination during vitrification and storage especially in the COVID-19 pandemic[J]. J Assist Reprod Genet, 2021, 38(3):681-688. doi: 10.1007/s10815-021-02062-y.
[19]	Marin L, Bedoschi G, Kawahara T, et al. History, Evolution and Current State of Ovarian Tissue Auto-Transplantation with Cryopreserved Tissue: a Successful Translational Research Journey from 1999 to 2020[J]. Reprod Sci, 2020, 27(4):955-962. doi: 10.1007/s43032-019-00066-9. pmid: 32046442
[20]	Yang Y, Wang Y, Xiao Z. Silver closed vitrification system versus slow freezing method for the cryopreservation of human ovarian tissue[J]. Cryo Letters, 2021, 42(4):245-250. pmid: 35363844
[21]	Sugishita Y, Taylan E, Kawahara T, et al. Comparison of open and a novel closed vitrification system with slow freezing for human ovarian tissue cryopreservation[J]. J Assist Reprod Genet, 2021, 38(10):2723-2733. doi: 10.1007/s10815-021-02297-9.
[22]	Galbinski S, Kowalewski LS, Grigolo GB, et al. Comparison between two cryopreservation techniques of human ovarian cortex: morphological aspects and the heat shock response (HSR)[J]. Cell Stress Chaperones, 2021, 27(2):97-106. doi: 10.1007/s12192-022-01252-6.
[23]	Olmo A, Barroso P, Barroso F, et al. The Use of High-Intensity Focused Ultrasound for the Rewarming of Cryopreserved Biological Material[J]. IEEE Trans Ultrason Ferroelectr Freq Control, 2021, 68(3):599-607. doi: 10.1109/TUFFC.2020.3016950.
[24]	Karimi S, Tabatabaei SN, Novin MG, et al. Nanowarming improves survival of vitrified ovarian tissue and follicular development in a sheep model[J]. Heliyon, 2023, 9(8):e18828. doi: 10.1016/j.heliyon.2023.e18828.
[25]	Zhang L, Chi M, Cheng Y, et al. Static magnetic field assisted thawing improves cryopreservation of mouse whole ovaries[J]. Bioeng Transl Med, 2024, 9(1):e10613. doi: 10.1002/btm2.10613.
[26]	Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion[J]. Fertil Steril, 2019, 112(6):1022-1033. doi: 10.1016/j.fertnstert.2019.09.013. pmid: 31843073
[27]	Dolmans MM, Donnez J. Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue[J]. Best Pract Res Clin Obstet Gynaecol, 2021, 70:63-80. doi: 10.1016/j.bpobgyn.2020.06.011.
[28]	Bystrova O, Lapina E, Kalugina A, et al. Heterotopic transplantation of cryopreserved ovarian tissue in cancer patients: a case series[J]. Gynecol Endocrinol, 2019, 35(12):1043-1049. doi: 10.1080/09513590.2019.1648413. pmid: 31373236
[29]	Xie B, Li J, Huang Y, et al. Assessing the impact of transplant site on ovarian tissue transplantation: a single-arm meta-analysis[J]. Reprod Biol Endocrinol, 2023, 21(1):120. doi: 10.1186/s12958-023-01167-6.
[30]	Oktay KH, Marin L. Comparison of orthotopic and heterotopic autologous ovarian tissue transplantation outcomes[J]. Fertil Steril, 2024, 121(1):72-79. doi: 10.1016/j.fertnstert.2023.10.015.
[31]	Cacciottola L, Donnez J, Dolmans MM. Ovarian tissue damage after grafting: systematic review of strategies to improve follicle outcomes[J]. Reprod Biomed Online, 2021, 43(3):351-369. doi: 10.1016/j.rbmo.2021.06.019. pmid: 34384692
[32]	Yang C, Chung N, Song C, et al. Promotion of angiogenesis toward transplanted ovaries using nitric oxide releasing nanoparticles in fibrin hydrogel[J]. Biofabrication, 2021,Dec 29, 14(1). doi: 10.1088/1758-5090/ac3f28.
[33]	Cacciottola L, Nguyen T, Chiti MC, et al. Long-Term Advantages of Ovarian Reserve Maintenance and Follicle Development Using Adipose Tissue-Derived Stem Cells in Ovarian Tissue Transplantation[J]. J Clin Med, 2020, 9(9):2980. doi: 10.3390/jcm9092980.
[34]	Cho J, Kim TH, Seok J, et al. Vascular remodeling by placenta-derived mesenchymal stem cells restores ovarian function in ovariectomized rat model via the VEGF pathway[J]. Lab Invest, 2021, 101(3):304-317. doi: 10.1038/s41374-020-00513-1. pmid: 33303971
[35]	Nazary Abrbekoh F, Salimi L, Saghati S, et al. Application of microneedle patches for drug delivery; doorstep to novel therapies[J]. J Tissue Eng, 2022,13:20417314221085390. doi: 10.1177/20417314221085390.
[36]	Yan L, Wang L, Wu J, et al. Multi-biofunctional graphene oxide-enhanced poly-L-lactic acid composite nanofiber scaffolds for ovarian function recovery of transplanted-tissue[J]. NPJ Regen Med, 2022, 7(1):52. doi: 10.1038/s41536-022-00236-5. pmid: 36114211
[37]	Sun TC, Liu XC, Yang SH, et al. Melatonin Inhibits Oxidative Stress and Apoptosis in Cryopreserved Ovarian Tissues via Nrf2/HO-1 Signaling Pathway[J]. Front Mol Biosci, 2020,7:163. doi: 10.3389/fmolb.2020.00163.
[38]	Damavandi M, Farrokh P, Zavareh S. Effect of Mouse Ovarian Vitrification on Promoter Methylation of Inhba and Inhbb in Granulosa Cells of Follicles[J]. Cryo Letters, 2021, 42(2):67-72. pmid: 33970982
[39]	Len JS, Koh W, Tan SX. The roles of reactive oxygen species and antioxidants in cryopreservation[J]. Biosci Rep, 2019, 39(8):BSR20191601. doi: 10.1042/BSR20191601.
[40]	Piras AR, Ariu F, Falchi L, et al. Resveratrol treatment during maturation enhances developmental competence of oocytes after prolonged ovary storage at 4 ℃ in the domestic cat model[J]. Theriogenology, 2020, 144:152-157. doi: 10.1016/j.theriogenology.2020.01.009. pmid: 31951984
[41]	Cao B, Qin J, Pan B, et al. Oxidative Stress and Oocyte Cryopreservation: Recent Advances in Mitigation Strategies Involving Antioxidants[J]. Cells, 2022, 11(22):3573. doi: 10.3390/cells11223573.
[42]	Marcantonini G, Bartolini D, Zatini L, et al. Natural Cryoprotective and Cytoprotective Agents in Cryopreservation: A Focus on Melatonin[J]. Molecules, 2022, 27(10):3254. doi: 10.3390/molecules27103254.
[43]	Cheng LY, Sun TC, Liu XC, et al. Melatonin induction of HSP90 expression exerts cryoprotective effect on ovarian tissue[J]. Cryobiology, 2021, 98:134-138. doi: 10.1016/j.cryobiol.2020.12.002. pmid: 33279510
[44]	Shu WH, Yang SH, Wei M, et al. Effects of sericin on oxidative stress and PI3K/AKT/mTOR signal pathway in cryopreserved mice ovarian tissue[J]. Cryobiology, 2023, 111:16-25. doi: 10.1016/j.cryobiol.2023.03.003. pmid: 36934957
[45]	Li Y, Hu Y, Zhu S, et al. Protective Effects of Reduced Glutathione and Ulinastatin on Xeno-transplanted Human Ovarian Tissue Against Ischemia and Reperfusion Injury[J]. Cell Transplant, 2021,30:963689721997151. doi: 10.1177/0963689721997151.
[46]	Olesen HØ, Pors SE, Jensen LB, et al. N-acetylcysteine protects ovarian follicles from ischemia-reperfusion injury in xenotransplanted human ovarian tissue[J]. Hum Reprod, 2021, 36(2):429-443. doi: 10.1093/humrep/deaa291.
[47]	Dolmans MM, von Wolff M, Poirot C, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers[J]. Fertil Steril, 2021, 115(5):1102-1115. doi: 10.1016/j.fertnstert.2021.03.008.
[48]	Lotz L, Bender-Liebenthron J, Dittrich R, et al. Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network[J]. Hum Reprod, 2022, 37(12):2787-2796. doi: 10.1093/humrep/deac225.
[49]	Erden M, Uyanik E, Demeestere I, et al. Perinatal outcomes of pregnancies following autologous cryopreserved ovarian tissue transplantation: a systematic review with pooled analysis[J]. Am J Obstet Gynecol, 2024, 231(5):480-489. doi: 10.1016/j.ajog.2024.04.012. pmid: 38621483
[50]	Karavani G, Wasserzug-Pash P, Mordechai-Daniel T, et al. Age-Dependent in vitro Maturation Efficacy of Human Oocytes - Is There an Optimal Age?[J]. Front Cell Dev Biol, 2021,9:667682. doi: 10.3389/fcell.2021.667682.
[51]	Dolmans MM, Amorim CA. FERTILITY PRESERVATION: Construction and use of artificial ovaries[J]. Reproduction, 2019, 158(5):F15-F25. doi: 10.1530/REP-18-0536.
[52]	Zhang YY, Yang W, Zhang Y, et al. HucMSC-EVs Facilitate In Vitro Development of Maternally Aged Preantral Follicles and Oocytes[J]. Stem Cell Rev Rep, 2023, 19(5):1427-1448. doi: 10.1007/s12015-022-10495-w.
[53]	Sönmezer M, Şükür YE, Saçıntı KG, et al. Safety of ovarian cryopreservation and transplantation in patients with acute leukemia: a case series[J]. Am J Obstet Gynecol, 2024, 230(1):79.e1-e10. doi: 10.1016/j.ajog.2023.08.032.